

# [Case Study] Exploring the Potential

[Aging & Healthspan, Disease Modeling](#) / By [Yoanne Clovis, Ph.D.](#)

How an anti-aging research company leveraged *C. elegans* to predict the most valuable longevity-enhancing compounds to develop



## Exploring the Potential

How an anti-aging research company leveraged *C. elegans* to predict the most valuable longevity-enhancing compounds to develop

“

While mammalian models are currently the gold standard for drug development, the enforced 3Rs and animal welfare guidelines have forced us to re-evaluate our development pipeline to include early stage in-vivo hypothesis testing. Understanding the biology of our compounds necessitates the use of an alternative model prior to going to more regulated, more resource and time-intensive models.

 NemaMetrix

## Overview:

Traditionally, clients of NemaMetrix's in-vivo testing services are pharmaceutical companies investigating chemically synthesized small molecules for efficacy on a specific gene target of interest. However, we have noticed a shift towards preventive medicine, which has given anti-aging companies a favorable environment in pursuing longevity and aging studies. These companies are tackling the aging process through pharmaceuticals, regenerative medicine, caloric restrictions, and dietary supplements.

One such company recently came to us wanting help identifying a compound mixture whose synergistic mode of action has the most positive effect on longevity. Unfortunately, this company's timeline was short - they needed preliminary data for their patents within the next 6-10 months.

## Solution:

## CATEGORIES

[17 Minutes of Science](#)

[Aging & Healthspan](#)

[CRISPR](#)

[Disease Modeling](#)

[Drug Discovery](#)

[Drug Toxicity](#)

[Gene Editing](#)

[News &](#)

[Announcements](#)

[Newsletter](#)

[View from the Bench](#)

We used the whole animal model *C. elegans* to perform a set of specific experiments designed by our experts to provide rapid and reliable data based on this anti-aging company's priorities.

### Benefits:

NemaMetrix is the market leader for early preclinical *in-vivo* testing using small animal models such as *C. elegans* and zebrafish to gain a better understanding of the efficacy, mode of action, toxicity and potential targets for novel compounds. Using the data that we provided, our client was able to apply for multiple patents in a timely manner.

[Download the Case Study](#)

### Share this article

Share 0

Tweet



[← Previous Post](#)

[Next Post →](#)



Right Model. Right Test. Right Insights.

#### 🔍 Search

#### In Vivo Solutions

- Lifespan & Healthspan Analysis
- In Vivo Toxicity Testing
- Custom In Vivo Testing

#### CRISPR Model Creation

- C. elegans* Transgenic Services
- Zebrafish Genome-Editing Services
- Humanized Models

#### Products

- Instruments
- Reagents
- Wormflow Software
- Consumables

#### Capabilities

#### 🗨️ Blog

#### Our Company

- About Us
- Our Team
- Our Values

#### Resources



- HElio Ortholog Gene Finder
- Disease Gene Finder
- Scientific Posters
- Video Gallery
- Product Documents
- Publications
- Return & Warranty Policy

#### Contact

- Product & Service Inquiries
- Technical Support Inquiry
- Contact Us
- Jobs

#### GDPR Policy

**A Licensed CRISPR Solutions Provider.**

1.844.663.8749 · support@invivobiosystems.com · Copyright © 2021 InVivo Biosystems All rights reserved. ·  Facebook ·  LinkedIn ·

 Twitter

